Responses
Clinical/translational cancer immunotherapy
Original research
Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma
Compose a Response to This Article
Other responses
No responses have been published for this article.